Chinese Journal of Pharmacovigilance ›› 2017, Vol. 14 ›› Issue (2): 90-94.
• Contents • Previous Articles Next Articles
XIONG Wei-yi ,DONG Duo*
Received:
2017-03-10
Revised:
2017-03-10
Online:
2017-02-20
Published:
2017-03-10
CLC Number:
XIONG Wei-yi ,DONG Duo. Review on the Immunization Strategy in Polio Post-eradication Era and Comparison of the Safety of Polio Vaccination Programs[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 90-94.
Add to citation manager EndNote|Ris|BibTeX
[1] World Health Organization. Polio vaccines: WHO position paper-March 2016[R/OL]. (2016-03-25)[2016-09-28]. http://www.who.int/wer/2016/wer9112.pdf?ua=1. [2] Beale A J. The development of IPV[M]//History of Vaccine Development. Springer New York, 2011: 179-187. [3] Sabin A B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world[J]. Journal of infectious diseases, 1985, 151(3): 420-436. [4] Wright P F, Kim-Farley R J, de Quadros C A, et al. Strategies for the global eradication of poliomyelitis by the year 2000[J]. New England journal of medicine, 1991, 325(25): 1774-1779. [5] World Health Organization. Polio Eradication and Endgame Strategic Plan, 2013-2018[R]. Geneva: WHO, 2013:1-3. [6] Jorba J. Update on vaccine-derived polioviruses-worldwide[J]. Morbidity and Mortality Weekly Report, 2016, 65(30):763-769. [7] Griffiths U K, Botham L, Schoub B D. The cost-effectiveness of alternative polio immunization policies in South Africa[J]. Vaccine, 2006, 24(29): 5670-5678. [8] Thompson K M, Tebbens R J D. Retrospective Cost Effectiveness Analyses for Polio Vaccination in the United States[J]. Risk Analysis, 2006, 26(6): 1423-1440. [9] Tucker A W, Isaacs D, Burgess M. Cost effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia[J]. Australian and New Zealand journal of public health, 2001, 25(5): 411-416. [10] Estívariz C F, Anand A, Gary H E, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial[J]. The Lancet Infectious Diseases, 2015, 15(8): 898-904. [11] World Health Assembly. Poliomyelitis. A68/21[EB/OL]. [2016-09-28].http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_21Add1-en.pdf [12] Hampton L M. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine—Worldwide, 2016[J]. MMWR. Morbidity and Mortality Weekly Report, 2016, 65(35):934-938. [13] World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016—conclusions and recommendations[R/OL]. (2016-05-27)[2016-09-28]. http://www.who.int/wer/2016/wer9121.pdf?ua=1. [14] Resik S, TejedaA, Sutter R W, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J]. New England Journal of Medicine, 2013, 368(5): 416-424. [15] 世卫组织西太平洋区域办事处. 疫苗安全性事件:沟通应对的管理[M/OL]. [2016-09-28]. http://iris.wpro.who.int/bitstream/handle/10665.1/12552/9789290617419_chi.pdf [16] Centers for Disease Control and Prevention. Poliomyelitis prevention in the US: introduction of a sequential vaccination schedule of IPV followed by OPV: recommendations of the Advisory Committee on Immunization Practices[J]. Morbidity and Mortality Weekly Report, 1997; 46 (RR-3):1-25. [17] WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year enquiry[J]. Bulletin of the World Health Organization, 1982, 60(2): 231-242. [18] Platt L R, Estívariz C F, Sutter R W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden[J]. Journal of Infectious Diseases, 2014, 210(suppl 1): 380-389. [19] Strebel P M, Ion-Nedelcu N, Baughman A L, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine—a risk factor for vaccine-associated paralytic poliomyelitis[J]. New England Journal of Medicine, 1995, 332(8): 500-506. [20] Oliveira L H, Struchiner C J. Vaccine-associated paralytic poliomyelitis in Brazil, 1989-1995[J]. RevistaPanamericana de SaludPública, 2000, 7(4): 219-224. [21] Stanley A P, Emmauel V.. 灭活脊髓灰质炎疫苗[M]//Stanley A P, Walter A O, Paul A O主编, 梁晓峰, 罗凤基, 封多佳, 主译. 疫苗学. 北京: 人民卫生出版社, 2011: 663-685. [22] Iqbal S, Shi J, Seib K, et al. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-2012[J]. The Lancet Infectious Diseases, 2015, 15(10): 1175-1182. [23] Alexander L N, Seward J F, Santibanez T A, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States[J]. The Journal of the American Medical Association, 2004, 292(14): 1696-1701. [24] Strategic Advisory Group of Experts on Immunization. Scientific evidence in support of: Note for the record: 5th meeting of the SAGE Working Group[R/OL].(2012-10-12)[2016-09-28] http://www.who.int/immunization/sage/meetings/2012/november/3__SAGE_WG_Scientific_Evidence22Oct2012.pdf [25] 罗会明, 余文周, 温宁, 等. 中国脊髓灰质炎疫苗使用历史回顾及免疫策略调整建议[J]. 中国疫苗和免疫, 2014, 20(2): 172-176. [26] 国家卫生计生委. 国家卫生计生委关于停用三价脊髓灰质炎减毒活疫苗的通知[EB/OL]. (2016-04-29)[2017-01-25].http://www.hncdc.com/Article/ShowArticle.asp?ArticleID=8322 [27] 温宁, 王兆南, 樊春祥, 等. 免疫规划专业人员对脊髓灰质炎疫苗使用知识态度行为的调查[J]. 中国疫苗和免疫, 2013, 18(6): 523-526. [28] 褚尧竹, 周玉清, 张旋, 等. 中国六省份儿童监护人脊髓灰质炎疫苗知识和接种意愿调查[J]. 中国疫苗和免疫, 2016, 22(3): 246-251. [29] 刘大卫, 郭飚, 曹玲生, 等. 全国2005-2006年疑似预防接种异常反应监测分析[J]. 中国计划免疫, 2007, 13(6): 505-513. [30] 武文娣, 刘大卫, 吴冰冰, 等. 全国2007-2008年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2009 (6): 481-490. [31] 武文娣, 刘大卫, 李克莉, 等. 全国2009年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2011, 17(2): 99-108. [32] 武文娣, 刘大卫, 李克莉, 等. 中国2010年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2012, 18(5): 385-397. [33] 武文娣, 李克莉, 郑景山, 等. 中国2011年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2013, 19(2): 97-109. [34] 武文娣, 刘大卫, 李克莉, 等. 中国2012年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2014, 20(1): 1-12. [35] 叶家楷, 李克莉, 许涤沙, 等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J]. 中国疫苗和免疫, 2015, 21(2): 121-131. [36] 叶家楷, 李克莉, 许涤沙, 等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J]. 中国疫苗和免疫, 2016, 22(2): 125-137. |
[1] | ZHAO Jie, GAO Minge, CHANG Hong, FAN Huixia. Pathogen Distribution, Drug Resistance and Drug Use in Neonates with Necrotizing Enterocolitis Complicated with Sepsis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 909-913. |
[2] | QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao. Research Progress in Integration Sites for Cellular and Gene Therapy Products [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727. |
[3] | LI Dong, SONG Yana, WANG Ligang, BIAN Rongrong, ZHAO Yan. Considerations for Establishing National Sentinel Hospitals for Medical Device Adverse Event Monitoring [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 780-785. |
[4] | ZHU Huijuan, REN Jingtian. Safety Risks of Human Rabies Immunoglobulin [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 786-789. |
[5] | LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793. |
[6] | LI Can, LIU Lehuan, CHEN Xia, QU Jianbo. Pharmacy of Chinese Medicine Compound Preparations Based on Human Experiences [J]. Chinese Journal of Pharmacovigilance, 2025, 22(5): 564-569. |
[7] | YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao. A National Pharmacovigilance Management System in a New Era [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281. |
[8] | LIU Ying, XIONG Shunyu, XIONG Huiyu, CAI Fei, XU Mengdan, WANG Qing, REN Wei, XU Yan. Methods for Assessment of MAH Compliance with GVP [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 282-285. |
[9] | ZHU Lan, SHAO Bo, ZHU Yan, DAI Jie, ZHONG Shiqi. Current Progress and Considerations in Updating the Safety Information in Labels of Chinese Traditional Patent Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 188-192. |
[10] | LI Wenlong, JIA Juanjuan, HUANG Haiwei, YAO Jing, ZHANG Chunqing, WANG Yan, ZHANG Hui. Developments and Prospects of Radiopharmaceuticals in China [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 37-42. |
[11] | SONG Fuyu, CAO Yi. Establishment of Key Performance Indicators for Drug Inspection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414. |
[12] | ZHAO Peipei, WEN Baoshu. Regulation of cellular and gene therapies at home and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1019-1024. |
[13] | YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028. |
[14] | SUN Yixin, NIE Xiaolu, WANG Xiaoling, GUO Peng. Comparative research on active post-marketing drug safety surveillance systems worldwide based on real-world data [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 892-899. |
[15] | WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru. Foreign methods for benefit-risk assessment of pharmaceutical products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||